Keyword Analysis & Research: ruxolitinib phosphate trade name

bing.com

https://www.bing.com/search?FORM=hlthdr&q=polycythemia+vera

Common brand names: JakafiOVERVIEWSIDE EFFECTSINTERACTIONSDOSAGEThis medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Call MD for fever, chills or persistent sore throat Not recommended when breast feeding Avoid sunlamps For cream products : Before use, important to read the Medication Guide. Wash hands before and after using. Apply a thin layer and rub in. Do not bandage unless told by doctor. Avoid contact with eyes, inside of nose or mouth. Protect skin from sunlight. For tablet products : If available, read the patient package insert. Tell MD immediately of easy bruising or bleeding. May make you dizzy. Use caution when driving. Avoid taking grapefruit juice/grapefruit with med. MD may need to reduce the dose before you stop it. Lab tests may be ordered to monitor therapy.

Call MD for fever, chills or persistent sore throat

Not recommended when breast feeding

Avoid sunlamps

For cream products : Before use, important to read the Medication Guide. Wash hands before and after using. Apply a thin layer and rub in. Do not bandage unless told by doctor. Avoid contact with eyes, inside of nose or mouth. Protect skin from sunlight.

For tablet products : If available, read the patient package insert. Tell MD immediately of easy bruising or bleeding. May make you dizzy. Use caution when driving. Avoid taking grapefruit juice/grapefruit with med. MD may need to reduce the dose before you stop it. Lab tests may be ordered to monitor therapy.

DA: 25 PA: 79 MOZ Rank: 7

cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/ruxolitinibphosphate

DA: 15 PA: 6 MOZ Rank: 41

wikipedia.org

https://en.wikipedia.org/wiki/Ruxolitinib

Ruxolitinib is a Janus kinase inhibitor. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, and by Novartis elsewhere in the world, under the brand name Jakavi. It was approved for medical use in the United States in 2011, and in the European Union in 2012. See more

DA: 17 PA: 86 MOZ Rank: 81

mayoclinic.org

https://www.mayoclinic.org/drugs-supplements/ruxolitinib-oral-route/description/drg-20075326

WEBApr 1, 2024 · Description and Brand Names. Drug information provided by: Merative, Micromedex® US Brand Name. Jakafi; Descriptions. Ruxolitinib is used to treat …

DA: 72 PA: 89 MOZ Rank: 88

mayoclinic.org

https://www.mayoclinic.org/drugs-supplements/ruxolitinib-oral-route/precautions/drg-20075326

DA: 67 PA: 63 MOZ Rank: 87

drugbank.com

https://go.drugbank.com/salts/DBSALT000156

WEBName. Ruxolitinib phosphate. Drug Entry. Ruxolitinib. Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor.

DA: 42 PA: 87 MOZ Rank: 94

drugs.com

https://www.drugs.com/mtm/ruxolitinib.html

WEBMar 2, 2023 · Brand name: Jakafi. Dosage form: oral tablet (10 mg; 15 mg; 20 mg; 25 mg; 5 mg) Drug class: Multikinase inhibitors. Medically reviewed by Drugs.com on Mar 2, … trade name

trade name

DA: 17 PA: 94 MOZ Rank: 97

medlineplus.gov

https://medlineplus.gov/druginfo/meds/a612006.html

WEBBrand names. Why is this medication prescribed? Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and … trade name

trade name

DA: 13 PA: 48 MOZ Rank: 34

nih.gov

https://pubchem.ncbi.nlm.nih.gov/compound/Ruxolitinib-phosphate

WEBRuxolitinib Phosphate | C17H21N6O4P | CID 25127112 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, … trade name

trade name

DA: 100 PA: 93 MOZ Rank: 76

drugbank.com

https://go.drugbank.com/drugs/DB08877

WEBRuxolitinib is a kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat … trade name

trade name

DA: 8 PA: 83 MOZ Rank: 23

cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/ruxolitinibphosphate

WEB(RUK-soh-LIH-tih-nib FOS-fayt) This page contains brief information about ruxolitinib phosphate and a collection of links to more information about the use of this drug, … trade name

trade name

DA: 100 PA: 14 MOZ Rank: 41

nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK570600/

WEBJun 5, 2023 · Ruxolitinib is a janus-activated kinase inhibitor (JAK) that selectively inhibits the JAK1 and JAK2 protein kinases. [1] . It is an oral medication approved by the FDA to treat high-risk myelofibrosis, … trade name

trade name

DA: 20 PA: 72 MOZ Rank: 86

ncats.io

https://drugs.ncats.io/substance/436LRU32H5

WEBRuxolitinib (trade names Jakafi and Jakavi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of …

DA: 46 PA: 9 MOZ Rank: 26